Alzheimer's Disease Neuroimaging Initiative 3 (ADNI 3)

ADNI 3Courtesy of the USC Laboratory of Neuro Imaging and Athinoula A. Martinos Center for Biomedical Imaging,
Consortium of the Human Connectome Project.

The Alzheimer’s Disease Neuroimaging Initiative (ADNI), is a landmark partnership and study that for 12 years has profoundly influenced our understanding of Alzheimer’s disease by identifying the earliest changes in brain structure and function that signal its onset and progression. The study is led by the National Institute on Aging with support from the FNIH and more than 30 organizations since its launch in 2004.

The third phase of ADNI launched in September 2016, building on the success of previous phases with new additions, including:

  • Recruiting 1,200 volunteers to join about 800 current participants to enrich the existing dataset;
  • Using state-of-the-art PET imaging techniques to monitor brain levels of tau, a protein that is often abnormal in Alzheimer’s patients;
  • Performing cutting-edge systems biology analyses to holistically assess complex interactions between the brain and body;
  • Assessing cognitive function through computer tests at home and in the doctor’s office and measure changes in subjects’ ability to handle money, which can be a warning sign of the disease.

ADNI 3 will run until July 31, 2022.

Read about the second phase of ADNI (ADNI 2) here

Read this information on ADNI from the National Institute of Aging.

Goals

  • Use state-of-the-art PET imaging techniques to monitor brain levels of tau, a protein that is often abnormal in Alzheimer’s patients.
  • Determine and define measures of cognition and function which detect AD progression in order to improve clinical trial outcomes.
  • Validate biomarker measures over time by correlating the results with “gold standard” clinical measurements and pathology.
  • Carryout a systems biology analyses to holistically assess complex interactions between the brain and body.
  • Assess cognitive function through computer tests at home and in the doctor’s office and measure changes in subjects’ ability to handle money.

Results & Accomplishments

Scientific Publications

Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials Weiner, Michael W.; Veitch, Dallas P.; Aisen, Paul S.; et al. Alzheimer's Dis Neuroimaging ALZHEIMERS & DEMENTIA 2017 13(4): E1-E85

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 Weiner, Michael W.; Veitch, Dallas P.; Aisen, Paul S.; et al. Alzheimer's Dis Neuroimaging Initi ALZHEIMERS & DEMENTIA 2015 11(7): 865-884

Media

FNIH Press Release (Sept. 8, 2016): Patient Advocacy Groups, Industry and Individuals Join Groundbreaking Public-Private Partnership to Continue Advancing Critical Alzheimer's Disease Research

Support

The FNIH is currently seeking funding commitments to support this program. For more information, please contact Development@fnih.org. Learn about the ADNI 3 Partnership Overview here

ADNI 3 Partners

 

Contact

Michael Biarnes, M.S., Scientific Project Manager, mbiarnes@fnih.org